Pathology Cng Mod Qipp Kb 071210
description
Transcript of Pathology Cng Mod Qipp Kb 071210
“Pathology Modernisation”
Ken BarrQIPP Network Director – North Mersey
Merseyside & Cheshire Pathology QIPP Network
www.networks.nhs.uk/nhs-networks/merseyside-cheshire-pathology-network
Why ‘modernise’ Carter and QIPP – 20% saving required in 4 years Good for patients, profession and... Good for finance – reducing PbR and direct access New technology – better, more accurate, quicker Opportunities for cross NHS working Share rare skills and technology/capacity Commissioners/GPs want a top notch accessible service – fit for
purpose and VFM Limit risk – growing private sector interest ‘Any willing provider’ - competition
Pathology Network: Merseyside and CheshirePopulation Served ~ 2.4m by 12 Trusts
Pathology Network
9 Trusts on 14 sites (incl. Warrington and STHK) 3 x Acute FT, 4 x Specialist FT, 2 x Acute Population served ~1.7m 5.7m requests pa = 26m tests 1,030 staff Direct budget £64m (09/10) QIPP savings target £14m
Latest Network Configuration
South SectorObservers
Wirral,Countess of
Chester
East SectorObservers
St. Helens & Knowsley
Warrington & Halton
North Mersey Sector
Aintree, RLBUHT,LWH, Alder Hey,
TWC, LHC, COCH,SONHST
Network Vision & Progress
“To provide an efficient and effective Pathology service for
our population that is patient focused and clinically led,
delivering measurable quality and performance that is
continually improving”
Singly managed
Hub & spoke model
Clinical leadership
IT connectivity
Pathology Board
Time to be bold and brave?
“Don’t be afraid to take a big step if one is indicated. You can’t cross a chasm in two
small jumps”
David Lloyd George
Multiple Hub – local needs
Many organisations
Single organisation
Business Case
Single managed network with single identity/employer
Remove historic organisational barriers and deliver services to population/GPs
‘Carter consolidated model’ – hub and spoke concept
Flexibility to reuse/rent space as available and affordable
Explore options for single business structure
NHS host, social enterprise, JV
Centralise multi-discipline, automated, non-urgent testing
Improve standardisation, quality, efficiency based on agreed TAT
Centralise specialist and sub-specialist services
Cost benefit analysis to include access to peer support, R&D, training, MDTs etc.
Clinically led integrated services
Respond to population/patient needs - improve access & patient experience
Increased efficiency
Reduce direct spend from £64m to £50m over four years (>20%)
Enablers: IT, Estate and Transport
• IT is vital to making the network viable – investment required
• Two way IT communication needed – order comms/L2L
• Sample tracking, specimen control, collection times, stats etc.
• Transport may require temperature regulated vehicles
• Needs to be flexible based on zones and ad-hoc capability
• Specialist companies available – need scaling
• Estate clearance house – inform hub opportunities
Biochemistry – Spoke Tests
Alanine transaminase (ALT)AlbuminAlkaline phosphataseAmmoniaAmylaseAspartate transaminaseBilirubin (total and conjugated)Blood gases and lactate (use ward-based instruments)BicarbonateCalcium[Cortisol]Carboxyhaemoglobin (ward)ChlorideC-reactive proteinCreatine kinaseCreatinineDigoxinEthanol (alcohol)GlucoseHuman chorionic gonadotrophin[Iron]
LithiumMagnesiumOsmolalityParacetamolPhosphateSalicylate[TFTs]Total protein[Transferrin]TroponinUrateUreaCSFGlucoseTotal proteinXanthochromia screenUrineCreatinineOsmolalityPotassiumPBGSodium
Copyright of Kent & Medway Pathology Network
Haematology ~ 3m tests
Urgent FBC and coagulationRoutine FBC and
coagulationFull Blood Transfusion
serviceESR GFST
Sickle screensMalaria investigations
B12 & Folate Hb Profile
G6PD Immunophenotyping
Bone Marrow Asp CSF Cytospin CytochemistryThrombophilia
LUPUS Factor assays (exc FVIII)
Plasma Heparin (Xa) HIT screen
Platelet AggregrationsMTHFR, Leiden, PTGM
HUB (60%)
SPOKE (40%)
Urgent FBC and ESR Urgent coagulation
Full Blood Transfusion serviceSickle screens
Malaria investigations
Copyright Kent & Medway Pathology Network
Next Steps
New return of cash releasing plans to DH on 7th January 2011
Develop Service Spec with external management support
by March 2011
CEO decision on business model/delivery method
by April 2011
Estate hub/spoke options by Trust/discipline
Commence consolidation during 2011/12
Meaningful consultation/communication with staff and stakeholders
To commence once CEOs have approved implementation
Project team to develop and deliver implementation plan 2011-2015
April 2011